Q/C TECHNOLOGIES, INC. (QCLS) Form SCHEDULE 13D/A — Nov 20, 2026
PharmaCyte Biotech filed an amended Schedule 13D disclosing a 49.99% beneficial ownership stake in Q/C Technologies (QCLS) — 8,446,093 common shares — after exchanging 851,304 Series G Long-Term Warrants for 4,982,272 common shares on November 18, 2026. The exchange was priced off QCLS's $0.3101 closing price, with no cash paid by PharmaCyte. As Required Holder of both the Series G and Series H Preferred Stock, PharmaCyte also entered an Omnibus Amendment Agreement with the issuer on November 20, 2026, amending the preferred stock certificates of designations to impose a 49.99% beneficial ownership limitation on conversions and warrant exercises.
Key figures
- Shares Owned
- 8446093
- Exchange Shares
- 4982272
- Percent Of Class
- 49.99%
- Exchange Warrants
- 851304
- Dividend Acquired Feb
- 127296
- Dividend Acquired Oct
- 42432
- Exchange Reference Price
- $0.3101 per share (closing price on last trading day before Consent Agreement)
- Beneficial Ownership Limit
- 49.99% of outstanding Common Stock
- Dividend Acquisition Price
- $3.3717 per share
- Series HMaturity Extended To
- September 2, 2027
- Series HMaturity Extended From
- March 2, 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.